November 2025 updates to the Universal Influenza Vaccine Technology Landscape include the following:
- Two new clinical trials of broadly protective and next-generation influenza vaccine candidates: NCT07215858, a phase 2 challenge trial NIAID’s beta-propiolactone-inactivated influenza virus cocktail (BPL-1357); and NCT07204964, a phase 2 trial of GSK’s mRNA-based multivalent seasonal influenza vaccine.
- Fitz-Patrick 2025 reported results from a phase 3 randomized trial (NCT05540522) on the safety, immunogenicity, and relative efficacy of Pfizer’s quadrivalent modRNA vaccine in preventing influenza among adults 18-64 years old.
- In a phase 1 randomized clinical trial, Deming 2025 demonstrated mucosal priming and broad cross-clade immune responses with a prime/boost approach, using intranasally administered rH5-NE, a recombinant H5 vaccine with a nanoemulsion adjuvant (W805EC), followed by intramuscular inactivated H5N1 vaccine.
- Akhtar 2025 reported that the CIVICs/Icahn chimeric HA (cH8/1N1 prime, cH5/1N1 boost) vaccine candidate induced a strong HA stalk-specific antibody response against heterologous influenza virus infections in a nonhuman primate model, and identified mechanisms associated with durable AS03 adjuvant-induced antibody responses.
- Using an infant African green monkey model, Crofts 2025 examined how initial exposure to influenza antigens affects immune responses to influenza virus and how early administration of NIAID’s adjuvanted HA stem nanoparticle, H1ssF+AddaVax, can shape imprinting via cross-reactive cellular immune memory responses.
- Huang 2025 reported on the preclinical development of a scalable pre-pandemic H5 vaccine with potential for cross-clade protection against drifted or newly emergent H5 influenza viruses, using a computationally designed nanoparticle, DIOSvax-H5inter Homotypic Nanocage.
For more recent updates and additional information, see the Landscape.